Clinical Trials Logo
  1. Home
  2. Lennox-Gastaut Syndrome
  3. NCT02175173

Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome Clinical Trial

Clinical Trial Summary

This surveillance's objectives are 1. Unknown adverse reactions 2. Incidences of adverse drug reaction 3. Efficacy during long-term administration 4. Factors considered to have effect to safety and effectiveness 5. Incidences of status epileptics, skin disorders and hyper sensitivity reaction, and central nervous system-related adverse events(ataxia , somnolence and/or dizzy, etc.)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02175173
Study type Observational
Source Eisai Inc.
Contact
Status Completed
Phase
Start date June 13, 2013
Completion date November 2, 2022
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT04133480 - Investigation of Cognitive Outcomes With Cannabidiol Oral Solution Phase 4
Recruiting NCT02632149 - Trial to Assess Vagus Nerve Stimulation Therapy in Children With Lennox-Gastaut Syndrome Phase 0
Active, not recruiting NCT05626634 - Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Phase 2
Completed NCT01151540 - A Long Term Extension Study of E2080 in Lennox-Gastaut Patients Phase 3
Completed NCT00552045 - Epilepsy Phenome/Genome Project
Completed NCT00004776 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome Phase 3
Withdrawn NCT03254680 - Turmeric as Treatment in Epilepsy N/A
Completed NCT01146951 - A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304) Phase 3
Completed NCT01991041 - European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS) N/A
Completed NCT01405053 - Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs Phase 3
Completed NCT02224573 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes Phase 3
Completed NCT00004729 - Ketogenic Diet for Child Epilepsy and Seizure Control N/A
Terminated NCT02815540 - The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy Phase 1/Phase 2
Withdrawn NCT02318537 - Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome Phase 3
Completed NCT01160770 - Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome Phase 3
Completed NCT03650452 - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies Phase 2
Withdrawn NCT01370486 - Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects Phase 4
Completed NCT02731300 - Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilot Study Phase 4
Completed NCT02224690 - A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults Phase 3